A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

June 15, 2017

Sponsor

Bristol Myers Squibb

Protocol Number

Bristol Myers Squibb CA017-003

To Learn More Call

(201)-510-0950